LCM
LCTX icon

LVM Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

LVM Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$15K – 138
2022
Q1 		$15K Hold
10,000
– – ﹤0.01% 138
2021
Q4 		$24K Hold
10,000
– – ﹤0.01% 130
2021
Q3 		$25K Buy
+10,000
New +$25.7K ﹤0.01% 126

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LVM Capital Management's LCTX Position: Q2 2022 in Review

LVM Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2022, closing a stake of 10,000 shares — an estimated $15K sold.

LVM Capital Management first reported a position in LCTX in Q3 2021 and held it in 3 quarters. The position peaked at $25K in Q3 2021. 101 funds tracked by Wall St. Rank hold LCTX as of Q2 2022.

  • LVM Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • LVM Capital Management sold 10,000 Lineage Cell Therapeutics shares in Q2 2022, an estimated $15K.
  • LVM Capital Management first reported a position in Lineage Cell Therapeutics in Q3 2021 and held it in 3 quarters.
  • LVM Capital Management's Lineage Cell Therapeutics position peaked at $25K in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2022.

Based on LVM Capital Management's 13F filing for Q2 2022, filed 14 Jul 2022.